|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2018
Schoffski, P.; Wozniak, A.; Kasper, B.; Aamdal, S.; Leahy, M. G.; Rutkowski, P.; Bauer, S.; Gelderblom, H.; Italiano, A.; Lindner, L. H.; Hennig, I.; Strauss, S.; Zakotnik, B.; Anthoney, A.; Albiges, L.; Blay, J. -Y.; Reichardt, P.; Sufliarsky, J.; Graaf, W. T. A. van der; Debiec-Rychter, M.; Sciot, R.; Cann, T. van; Marreaud, S.; Raveloarivahy, T.; Collette, S. und Stacchiotti, S.
(2018):
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
In: Annals of Oncology, Bd. 29, Nr. 3: S. 758-765
Elander, N. O.; Aughton, K.; Ghaneh, P.; Neoptolemos, J. P.; Palmer, D. H.; Cox, T. F.; Campbell, F.; Costello, E.; Halloran, C. M.; Mackey, J. R.; Scarfe, A. G.; Valle, J. W.; McDonald, A. C.; Carter, R.; Tebbutt, N. C.; Goldstein, D.; Shannon, J.; Dervenis, C.; Glimelius, B.; Deakin, M.; Charnley, R. M.; Anthoney, A.; Lerch, M. M.; Mayerle, J.; Olah, A.; Buchler, M. W. und Greenhalf, W.
(2018):
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
In: British Journal of Cancer, Bd. 118, Nr. 8: S. 1084-1088
2017
Schoffski, P.; Wozniak, A.; Stacchiotti, S.; Rutkowski, P.; Blay, J.-Y.; Lindner, L. H.; Strauss, S. J.; Anthoney, A.; Duffaud, F.; Richter, S.; Grünwald, V.; Leahy, M. G.; Reichardt, P.; Sufliarsky, J.; Graaf, W. T. van der; Sciot, R.; Debiec-Rychter, M.; Cann, T. van; Marreaud, S.; Lia, M.; Raveloarivahy, T.; Collette, L. und Bauer, S.
(2017):
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
In: Annals of Oncology, Bd. 28, Nr. 12: S. 3000-3008